ALK-Positive NSCLC Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Laura Chow, MD, FRCPC, discusses the clinical significance of the ASCEND-7 trial, which examined the intracranial effects of ceritinib in ALK-positive NSCLC.
View More
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
View More
Solange Peters, MD, PhD, Chair, Medical Oncology, Lausanne University Hospital, Switzerland, discusses the ALEX study and the opportunities it presents for patients with ALK-positive non–small-cell…
View More
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
View More
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
View More
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
View More
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
View More
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
View More
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
View More
Stay in the know.
OncNet Newsletter